Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Manreet Basra

Cardiovascular Disease Stockton, CA Medical Doctor

NPI 1114157484 CMS profile 50554

1801 E March Ln Ste D400, Stockton, CA 95210

Open in the dashboard

General payments

$7,440

276 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Manreet Basra of Stockton, CA is reported in the CMS Open Payments database as having received $7,440 across 276 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $652 21
2024 General $657 27
2023 General $2,573 67
2022 General $1,080 56
2021 General $668 34
2020 General $237 13
2019 General $1,573 58

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Manreet Basra
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Manreet Basra were reported at $652. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Manreet Basra Cardiovascular Disease median Middle half National median
2019 $1,573 $450 $127–$1,392 $163
2020 $237 $242 $77–$751 $114
2021 $668 $335 $101–$1,037 $132
2022 $1,080 $395 $121–$1,211 $149
2023 $2,573 $443 $136–$1,283 $160
2024 $657 $450 $136–$1,323 $164
2025 $652 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $1,882 22 payments
  2. Boston Scientific Corporation $1,429 46 payments
  3. Janssen Pharmaceuticals, Inc $497 32 payments
  4. Novartis Pharmaceuticals Corporation $464 25 payments
  5. E.R. Squibb & Sons, L.L.C. $460 26 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $413 21 payments
  7. Medtronic, Inc. $337 10 payments
  8. Sanofi-Aventis U.S. LLC $279 14 payments
  9. Amgen Inc. $238 14 payments
  10. Pfizer Inc. $175 8 payments
  11. Other $1,266 58 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,316 271 payments
  2. Travel and Lodging $1,103 4 payments
  3. Education $20 1 payment
Products named General payments · program years 2019–2025
  1. MITRACLIP $1,277 11 payments
  2. WATCHMAN $582 4 payments
  3. XARELTO $497 32 payments
  4. JARDIANCE $361 19 payments
  5. ELIQUIS $342 20 payments
  6. WATCHMAN FLX $247 14 payments
  7. Repatha $238 14 payments
  8. ENTRESTO $207 12 payments
  9. LEQVIO $193 9 payments
  10. WATCHMAN Access System $192 10 payments
  11. Other $3,565 145 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

4,011

Median for Cardiology: 2,533

Drug cost

$900,065

Median for Cardiology: $485,213

Branded share of claims

25.3%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 416 $437,341
Xarelto Rivaroxaban Brand 198 $212,275
Entresto Sacubitril/Valsartan Brand 77 $95,231
Jardiance Empagliflozin Brand 81 $80,581
Multaq Dronedarone Hcl Brand 19 $29,212
Praluent Pen Alirocumab Brand 18 $11,619
Metoprolol Succinate Generic 340 $5,168
Carvedilol Generic 394 $3,783
Losartan Potassium Generic 424 $3,781
Atorvastatin Calcium Generic 325 $3,281

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$316,984

Of which drugs: $1,111

Medicare patients

1,612

Average age 75

Services billed

5,119

939 women, 673 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Diabetes 42%
Chronic kidney disease 38%
Ischemic heart disease 37%
Heart failure 34%
Atrial fibrillation 33%
COPD 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 50 200 $1,111

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $89
$89 — —
ELIQUIS
  • PFIZER INC. $33
  • E.R. Squibb & Sons, L.L.C. $30
$63 416 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $52
$52 81 —
XARELTO
  • Janssen Pharmaceuticals, Inc $17
$17 198 —
TYVASO
  • United Therapeutics Corporation $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

276 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record